ArticleBMJ open2025
Kidney failure risk equation to predict kidney transplant failure in individuals with an eGFR<30 mL/min/1.73 m
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo externally validate and subsequently repurpose/recalibrate the easily accessible kidney failure risk equation (KFRE) for a prevalent transplant population with an estimated glomerular filtration rate (eGFR)<30 mL/min/1.73 m². It also aims to evaluate the recalibrated KFRE's potential to improve clinical practice with a clinical utility assessment.
designRetrospective cohort study using UK Renal Registry data.
setting68 adult UK kidney centres.
participants4092 patients with grafts at least 2 years old and eGFR<30 mL/min/1.73 m PRIMARY OUTCOME MEASURE: Death-censored allograft failure at 2 years, defined as dialysis initiation, re-transplantation or, in the absence of the former two, the recorded date of transplant failure. PROGNOSTIC MODEL VALIDATION: The KFRE was calculated at baseline using the 2-year, 8-variable non-North American KFRE, and performance was assessed using Harrell's C-statistic and calibration plots. The model was recalibrated using Cox Regression (2009-2013 cohort) and temporally validated using the 2014-2018 cohort. Clinical utility was assessed using decision-curve analysis, estimating per-100-patient gains in timely planning and reductions in unnecessary interventions compared with eGFR triggers.
resultsThe original KFRE had excellent discrimination but was miscalibrated, underpredicting graft failure. Temporal validation demonstrated that the performance of the recalibrated KFRE could be maintained across time periods (Harrell's C-index of 0.81 (95% CI 0.80 to 0.83); O/E (Observed/Expected events) ratio 1.00 (95% CI 0.93 to 1.07). It identified 9/100 more patients for timely intervention and 13/100 more for whom intervention could be delayed compared with a late clinical trigger of an eGFR<15 mL/min/1.73 m
conclusionsWhile there are other prognostic models, this is the first study to focus on the understudied and clinically important cohort of patients with an eGFR<30 mL/min/1.73 m², offering more relevant 2-year predictions. For this underserved population, we present an easily accessible model that is robust to temporal and case-mix differences, demonstrates clinical utility and has the potential to improve daily clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.